ACBD3 and bladder transitional cell carcinoma: Figure 3 showed that ACBD3 expression was statistically different among the immune subtypes of nine tumors, including BLCA (Fig. 3A), HNSC (Fig. 3B), STAD (Fig. 3C), SKCM (Fig. 3D), sarcoma (SARC) (Fig. 3E), ovarian serous cystadenocarcinoma (OV) (Fig. 3F), LUSC (Fig. 3G), LIHC (Fig. 3H), and GBM (Fig. 3I).